AlphaMadera's AlphaVal page computes Leggett & Platt, Incorporated's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag LEG as undervalued, fairly valued, or overvalued.

What is Leggett & Platt, Incorporated's fair value?

Fair value for LEG is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value LEG?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from LEG's most recent reported fundamentals.

LEG - Leggett & Platt, Incorporated

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $11.67 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Undervalued Strong

Trading 65.1% below fair value

Current Price $10.94

Bear Case $27.47 151.1% upside ($27.47 - $10.94) / $10.94 = 151.1% $2.27 × 14x P/E

Fair Value $31.39 186.9% upside ($31.39 - $10.94) / $10.94 = 186.9% $2.27 × 16x P/E

Bull Case $35.31 222.8% upside ($35.31 - $10.94) / $10.94 = 222.8% $2.27 × 18x P/E

Adjust Assumptions

P/E Multiple

16.0x

Adjusted EPS

2.27$

Key Value Driver

Normalized P/E multiple (16x base case)

Implied Market Multiple 4.8x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $11.67 from 14 analysts, using a 20% weight on analyst consensus. That produces an estimated intrinsic value of $31.39 per share.

Warnings

⚠ The company's reported profits differ from official accounting profits by 34%. Check what costs are being left out of the adjusted number.

ℹ Wall Street's average price target is $11.67 (from 14 analysts). Our estimate is 211% above the consensus -- consider that gap carefully.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples